Efficacy and Safety Study of IBI-10090 in Patients Undergoing Cataract Surgery

Stopped early · Phase 2

Conditions studied: Inflammatory Reaction Due to Ocular Lens Prosthesis

In brief

This study will test the efficacy and safety of IBI-10090 for the reduction of ocular inflammation after cataract surgery.

Key facts

Study ID

NCT01048593

Run by

ICON Bioscience Inc

People needed

6

Starts

2010-01-01

Expected to finish

2010-06-01

Last updated by the study team

2018-12-04

Who can join

Age: 40 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Male or female patients 40 years of age scheduled for unilateral cataract surgery (phacoemulsification or extracapsular extraction) with posterior chamber intraocular lens implantation.

You may not qualify if…

• Patients who have used any ocular, topical or oral corticosteroids within 7 days prior to Day 0.
• Patients who have used topical ocular NSAIDs in the study eye within 15 days prior to screening.
• Patients with any signs of intraocular inflammation in either eye at screening.
• Patients who have received any prior intravitreal injections in the study eye.

Where it is running

• Altos Eye Physicians — Los Altos, California, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.